Until Sidney shows some revenues, expect share price to sit around that 05 area with the occasional and short-lived bumps in price from PR's. Trade volume will continue to be slim to none. Time is not on our side the longer this takes. The rest of the diabetes health management world is not sitting still.
While some on this board will continue to assert that ALRT's product is unique and best suited for diabetes health management, companies like Teledoc Health (who acquired Livongo for $18.5B) are not sitting still. In addition, there are a number of players who have written diabetes management software apps like Emperra, Sanofi, Tandem, Dexcom, MyLife, Acon, Bionime....
I'm cautiously optimistic and continue to hold, but also getting concerned with how long this is taking and ALRT's ability to continue to secure funding.
News 
Market Data 
Discover 
